Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Intercept Pharmaceuticals Identifier:
First received: November 14, 2011
Last updated: March 3, 2015
Last verified: March 2015